力生製藥(002393.SZ):中央藥業將以自籌資金追加項目投資11055萬元
格隆匯4月10日丨力生製藥(002393.SZ)公佈,公司於2018年1月30日召開的2018年第一次臨時股東大會審議通過了《關於中央藥業投資設立全資子公司並投資建設原料藥基地項目的議案》。
天津市中央藥業有限公司(“中央藥業”)在滄州臨港經濟技術開發區東區設立全資子公司河北崑崙製藥有限公司(“崑崙製藥”),註冊資本為2000萬元人民幣,並由崑崙製藥為實施主體,建設原料藥基地。該項目將分期建設,一期投資為15416萬元。截至目前,該項目建設進展情況良好,已完成6個單體建築封頂工作,累計投入資金6295萬元。
由於該項目所在地園區調整投資要求、規劃條件變化以及安全、環保相關標準提高等諸多因素影響,該項目實際開展情況與原可行性研究報告已有了較大差異,公司擬將該項目一期總投資額由原15416萬元,增加至26471萬元,新增投資11055萬元,中央藥業將以自籌資金的方式解決。該項目追加投資事項尚需提交股東大會審議批准方可實施。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.